Affiliation:
1. Maastricht University Faculty of Health, Medicine and Life Sciences: Maastricht Universitair Medisch Centrum+
2. Katholieke Universiteit Leuven UZ Leuven: Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven
3. Geneva University Hospitals: Hopitaux Universitaires Geneve
4. University Hospital Antwerp: Universitair Ziekenhuis Antwerpen
Abstract
Abstract
Background: A combined vestibular (VI) and cochlear implant (CI) device, also known as the vestibulocochlear implant (VCI), was previously developed to restore both vestibular and auditory function. A new refined prototype is currently being investigated. This prototype allows for concurrent multichannel vestibular and cochlear stimulation. Although recent studies showed that VCI stimulation enables compensatory eye, body and neck movements, the constraints in these acute study designs prevent them from creating more general statements over time. Moreover, the clinical relevance of potential VI and CI interactions is not yet studied. The VertiGO! Trial aims to investigate the safety and efficacy of prolonged daily motion modulated stimulation with a multichannel VCI prototype.
Methods: A single-center clinical trial will be carried out to evaluate prolonged VCI stimulation, assess general safety and explore interactions between the CI and VI. A single-blind randomized controlled cross-over design will be implemented to evaluate the efficacy of three types of stimulation (i.e. two types of motion-modulated stimulation versus unmodulated baseline stimulation). Furthermore, this study will provide a proof-of-concept for a VI rehabilitation program. A total of minimum eight, with a maximum of 13, participants suffering from bilateral vestibulopathy and severe sensorineural hearing loss in the ear to implant will be included and followed over a five-year period. A VCI will be implanted into all three semicircular canals via the intralabyrinthine approach, and into the cochlea. After CI-rehabilitation, the VI will be fitted and one day of baseline testing will be planned before three periods of prolonged VI stimulation take place. Efficacy will be evaluated by collecting functional (i.e. image stabilization) and more fundamental (i.e. vestibulo-ocular reflexes, self-motion perception) outcomes. Hearing performance with a VCI and patient-reported outcomes will be included as well.
Discussion: The proposed schedule of fitting, stimulation and outcome testing allows for a comprehensive evaluation of the feasibility and long-term safety of a multichannel VCI prototype. This design will give insights into vestibular and hearing performance during VCI stimulation. Results will also provide insights into the expected daily benefit of prolonged VCI stimulation, paving the way for cost-effectiveness analyses and a more comprehensive clinical implementation of electrical vestibulocochlear stimulation in the future.
Trial registration: ClinicalTrials.gov: NCT04918745. Registered 28 April 2021
Publisher
Research Square Platform LLC
Reference87 articles.
1. Lucieer FMP, Van Hecke R, van Stiphout L, Duijn S, Perez-Fornos A, Guinand N, et al. Bilateral vestibulopathy: beyond imbalance and oscillopsia. J Neurol [Internet]. 2020; Available from: https://doi.org/10.1007/s00415-020-10243-5.
2. Causes and management;Tilikete C;Curr Opin Neurol,2011
3. Quality of life of patients with bilateral vestibulopathy;Guinand N;Ann Otol Rhinol Laryngol,2012
4. Bilateral Vestibular Hypofunction: Challenges in Establishing the Diagnosis in Adults;Berg R;Orl,2015
5. Clinical observational gait analysis to evaluate improvement of balance during gait with vibrotactile biofeedback;Janssen M;Physiother Res Int,2012